Clinical features of 162 fatal cases of COVID-19: a multi-center, retrospective study
Abstract Understanding the epidemiological and clinical characteristics of fatal cases infected with SARS-CoV-2 is import to develop appropriate preventable intervention programs in hospitals. Demographic data, clinical symptoms, clinical course, co-morbidities, laboratory findings, CT scans, treatments and complications of 162 fatal cases were retrieved from electric medical records in 5 hospitals of Wuhan, China. The median age was 69.5 years old (IQR: 63.0-77.25; range: 29-96). 112 (69.1%) cases were men. Hypertension (45.1%) was the most common co-morbidity, but 59 (36.4%) cases had no co-morbidity. At admission, 131 (81.9%) cases were assessed as severe or critical. However, 39 (18.1%) were assessed as moderate. Moderate cases had a higher prevalence of hypertension and chronic lung disease comparing with severe or critical cases (P<0.05, respectively). 126 (77.8%) and 132 (81.5%) cases received antiviral treatment and glucocorticoids, respectively. 116 (71.6%) cases were admitted to ICU and 137 (85.1%) cases received mechanical ventilation. Respiratory failure or acute respiratory distress syndrome (93.2%) was the most common complication. The young cases of COVID-19, without co-morbidity and in a moderate condition at admission could develop fatal outcome. We need to be more cautious in case management of COVID-19 for preventing the fatal outcomes..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 28. Juli Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Xianlong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-29357/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA03391642X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA03391642X | ||
| 003 | DE-627 | ||
| 005 | 20230429193344.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-29357/v1 |2 doi | |
| 035 | |a (DE-627)XRA03391642X | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-29357/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Xianlong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical features of 162 fatal cases of COVID-19: a multi-center, retrospective study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Understanding the epidemiological and clinical characteristics of fatal cases infected with SARS-CoV-2 is import to develop appropriate preventable intervention programs in hospitals. Demographic data, clinical symptoms, clinical course, co-morbidities, laboratory findings, CT scans, treatments and complications of 162 fatal cases were retrieved from electric medical records in 5 hospitals of Wuhan, China. The median age was 69.5 years old (IQR: 63.0-77.25; range: 29-96). 112 (69.1%) cases were men. Hypertension (45.1%) was the most common co-morbidity, but 59 (36.4%) cases had no co-morbidity. At admission, 131 (81.9%) cases were assessed as severe or critical. However, 39 (18.1%) were assessed as moderate. Moderate cases had a higher prevalence of hypertension and chronic lung disease comparing with severe or critical cases (P<0.05, respectively). 126 (77.8%) and 132 (81.5%) cases received antiviral treatment and glucocorticoids, respectively. 116 (71.6%) cases were admitted to ICU and 137 (85.1%) cases received mechanical ventilation. Respiratory failure or acute respiratory distress syndrome (93.2%) was the most common complication. The young cases of COVID-19, without co-morbidity and in a moderate condition at admission could develop fatal outcome. We need to be more cautious in case management of COVID-19 for preventing the fatal outcomes. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Ding, Guoyong |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Luyu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Shouzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ang |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jiangtao |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Jianyou |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Zhuanzhuan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ruining |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Mingxia |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xizhu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Quan |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Weijia |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Zhigang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 28. Juli |
| 773 | 1 | 8 | |g year:2022 |g day:28 |g month:07 |
| 856 | 4 | 0 | |u https://doi.org/10.1097/EC9.0000000000000026 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-29357/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 28 |c 07 | ||